|
  
- 积分
- 97
- 威望
- 97
- 包包
- 3142
|

本帖最后由 bobo 于 2009-6-28 08:34 编辑 % K/ f1 [) X6 l$ E
9 ]* \9 {- t1 W) W0 ~表观遗传学与干细胞——2009年亚洲生物高峰论坛录制(音频mp3)
+ \1 L9 Y, i( h' A! k4 t) }5 v& B8 S
. R; q% O/ g6 }: C" u8 Y( Y# m g+ c( V0 Z: r
回复为ppt# O& I' e: }# A4 M
摘要:. E3 }8 U) j7 s- Q3 `0 u. n
9 O# y, i5 n0 R6 m8 R. K1 xHongkui Deng1 u& x/ m# p$ v' D; g! ?
" O6 K% O1 ^2 K9 g4 ?
Laboratory of Stem Cell and Generative Biology, College of Life Sciences, Peking University, Beijing 100871, China.9 |7 M1 c5 z3 \: H( n
$ c$ Q" O; r* G9 J! lHuman pluripotent stem cells represent a potentially unlimited source of functional pancreatic endocrine lineage cells. We established a new highly efficient approach to induce human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells to differentiate into mature insulin-producing cells in a chemical-defined culture system. The differentiated cells obtained by this approach comprised nearly 25% insulin-positive cells as assayed by flow cytometry analysis, which released insulin/C-peptide in response to glucose stimuli in a manner comparable to that of adult human islets. Most of these insulin-producing cells co-expressed mature beta cell-specific markers such as NKX6-1 and PDX1, indicating a similar gene expression pattern to adult islet beta cells in vivo. This work provides a new model to study the mechanism of human pancreatic specialization and maturation in vitro, and enhances the possibility of utilizing patient-specific iPS cells for the treatment of diabetes
* B: P4 M/ q- z, _, ?+ v% W( ]
' e; `, R: d% F0 D& b7 l2 H回复为ppt
) @$ a4 k3 o! h/ ?6 W0 I0 M1 T9 c x( H( x/ h5 z
1 f; K( v T9 f
% B6 Y7 V8 o+ N N5 W( f. Z0 q
2 Q# I: Y2 g2 N+ p: @; W |
附件: 你需要登录才可以下载或查看附件。没有帐号?注册
|